TRDA (Entrada Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TRDA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | MPM BioVentures 2018 GP LLC | 10%+ Owner | Sell | — | — |
| 2026-09-09 | MPM BioVentures 2014, L.P. | 10%+ Owner | Sell | — | — |
| 2026-09-03 | Dipal Doshi | CEO | F | — | — |
| 2026-09-03 | Nathan J Dowden | President & COO | F | — | — |
| 2026-09-03 | KORY JAMES WENTWORTH | Chief Financial Officer | F | — | — |
| 2026-09-03 | Natarajan Sethuraman | President, Research & Develop. | F | — | — |
| 2026-09-03 | MPM Asset Management Investors BV2014 LLC | 10%+ Owner | Sell | — | — |
| 2026-09-03 | MPM BIOVENTURES 2018, L.P. | 10%+ Owner | Sell | — | — |
| 2026-08-31 | MPM BioVentures 2014 GP LLC | 10%+ Owner | Sell | — | — |
| 2026-08-31 | MPM BioVentures 2018 GP LLC | 10%+ Owner | Sell | — | — |
| 2026-08-26 | MPM BioVentures 2014 GP LLC | 10%+ Owner | Sell | — | — |
| 2026-08-26 | MPM BioVentures 2018 GP LLC | 10%+ Owner | Sell | — | — |
| 2026-08-10 | 5AM Partners V, LLC | 10%+ Owner | Sell | — | — |
| 2026-08-10 | KUSH PARMAR | Director | Sell | — | — |
| 2026-08-03 | KUSH PARMAR | Director | Sell | — | — |
| 2026-08-03 | Andrew J. Schwab | 10%+ Owner | Sell | — | — |
| 2026-06-12 | Gina Chapman | Director | A | — | — |
| 2026-06-12 | Maha Radhakrishnan | Director | A | — | — |
| 2026-06-12 | Bernhardt G Zeiher | Director | A | — | — |
| 2026-06-12 | Mary Thistle | Director | A | — | — |
| 2026-06-12 | PETER S KIM | Director | A | — | — |
| 2026-06-12 | KUSH PARMAR | Director | A | — | — |
| 2026-05-21 | Bernhardt G Zeiher | Director | Buy | — | — |
| 2026-05-04 | Nathan J Dowden | President & COO | MIXED | — | — |
| 2026-05-04 | Natarajan Sethuraman | President, Research & Develop. | Sell | — | — |
| 2026-04-02 | KORY JAMES WENTWORTH | Chief Financial Officer | Sell | — | — |
| 2026-03-11 | KORY JAMES WENTWORTH | Chief Financial Officer | Sell | — | — |
| 2026-03-11 | Nathan J Dowden | President & COO | Sell | — | — |
| 2026-03-06 | KORY JAMES WENTWORTH | Chief Financial Officer | Sell | — | — |
| 2026-03-03 | Dipal Doshi | CEO | MIXED | — | — |
| 2026-03-03 | Natarajan Sethuraman | President, Research & Develop. | MIXED | — | — |
| 2026-03-03 | Nathan J Dowden | President & COO | MIXED | — | — |
| 2026-03-03 | KORY JAMES WENTWORTH | Chief Financial Officer | MIXED | — | — |
| 2025-11-24 | KORY JAMES WENTWORTH | Chief Financial Officer | Sell | — | — |
| 2025-11-24 | JULIAN BAKER | 10%+ Owner | Buy | — | — |
| 2025-11-18 | KUSH PARMAR | Director | Sell | — | — |
| 2025-11-18 | 5AM Partners V, LLC | 10%+ Owner | Sell | — | — |
| 2025-11-12 | Baker Bros. Advisors (GP) LLC | 10%+ Owner | Buy | — | — |
| 2025-09-04 | KORY JAMES WENTWORTH | Chief Financial Officer | F | — | — |
| 2025-09-04 | Nathan J Dowden | President & COO | F | — | — |
| 2025-09-04 | Dipal Doshi | CEO | F | — | — |
| 2025-09-04 | Natarajan Sethuraman | President, Research & Develop. | F | — | — |
| 2025-07-11 | KUSH PARMAR | Director | Sell | — | — |
| 2025-07-11 | 5AM Partners V, LLC | 10%+ Owner | Sell | — | — |
| 2025-07-01 | 5AM Partners V, LLC | 10%+ Owner | Sell | — | — |
| 2025-07-01 | KUSH PARMAR | Director | Sell | — | — |
| 2025-06-18 | PETER S KIM | Director | Buy | — | — |
| 2025-06-12 | KUSH PARMAR | Director | A | — | — |
| 2025-06-12 | PETER S KIM | Director | A | — | — |
| 2025-06-12 | Mary Thistle | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,541,670 | — |
| — | 10%+ Owner | 4,425,784 | — |
| — | Director | 4,425,784 | — |
| — | 10%+ Owner | 4,402,849 | — |
| — | 10%+ Owner | 4,381,062 | — |
| — | 10%+ Owner | 4,279,426 | — |
| — | 10%+ Owner | 4,144,952 | — |
| — | 10%+ Owner | 4,144,952 | — |
| — | 10%+ Owner | 4,106,452 | — |
| — | 10%+ Owner | 3,941,623 | — |
| — | 10%+ Owner | 3,913,952 | — |
| — | 10%+ Owner | 3,877,094 | — |
| — | 10%+ Owner | 2,495,385 | — |
| — | Director | 1,093,313 | — |
| — | 10%+ Owner | 954,420 | — |
| — | CEO | 517,290 | — |
| — | 10%+ Owner | 381,338 | — |
| — | 10%+ Owner | 360,122 | — |
| — | President, Research & Develop. | 214,238 | — |
| — | President & COO | 196,060 | — |
| — | Chief Financial Officer | 117,277 | — |
| — | Director | 92,412 | — |
| — | Chief Medical Officer | 41,330 | — |
| — | Director | 37,864 | — |
| — | Director | 5,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TRDA quote page; the site-wide leaderboard is on the insider transactions hub.